Ascendis Pharma A/S (NASDAQ:ASND) and Appili Therapeutics (OTCMKTS:APLIF) Critical Review

Ascendis Pharma A/S (NASDAQ:ASND) and Appili Therapeutics (OTCMKTS:APLIF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Appili Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57 million	16.12	-$258.00 million	$8.67	24.27
Appili Therapeutics	$70,000.00	22.43	-$1.89 million	($0.03)	-0.40

Appili Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Appili Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ascendis Pharma A/S and Appili Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Appili Therapeutics	N/A	N/A	-190.26%

Analyst Ratings

This is a summary of recent recommendations and price targets for Ascendis Pharma A/S and Appili Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1	0	16	2	3.00
Appili Therapeutics	0	0	0	0	0.00

Ascendis Pharma A/S presently has a consensus price target of $295.39, suggesting a potential upside of 40.36%. Given Ascendis Pharma A/S’s stronger consensus rating and higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Appili Therapeutics.

Summary

Ascendis Pharma A/S beats Appili Therapeutics on 9 of the 11 factors compared between the two stocks.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.